These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24107081)

  • 1. Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis.
    Shirude PS; Madhavapeddi P; Naik M; Murugan K; Shinde V; Nandishaiah R; Bhat J; Kumar A; Hameed S; Holdgate G; Davies G; McMiken H; Hegde N; Ambady A; Venkatraman J; Panda M; Bandodkar B; Sambandamurthy VK; Read JA
    J Med Chem; 2013 Nov; 56(21):8533-42. PubMed ID: 24107081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, chemical synthesis of 3-(9H-fluoren-9-yl)pyrrolidine-2,5-dione derivatives and biological activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis.
    Matviiuk T; Rodriguez F; Saffon N; Mallet-Ladeira S; Gorichko M; de Jesus Lopes Ribeiro AL; Pasca MR; Lherbet C; Voitenko Z; Baltas M
    Eur J Med Chem; 2013; 70():37-48. PubMed ID: 24140915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New coumarin linked thiazole derivatives as antimycobacterial agents: Design, synthesis, enoyl acyl carrier protein reductase (InhA) inhibition and molecular modeling.
    Kassem AF; Sabt A; Korycka-Machala M; Shaldam MA; Kawka M; Dziadek B; Kuzioła M; Dziadek J; Batran RZ
    Bioorg Chem; 2024 Sep; 150():107511. PubMed ID: 38870705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis.
    Pedgaonkar GS; Sridevi JP; Jeankumar VU; Saxena S; Devi PB; Renuka J; Yogeeswari P; Sriram D
    Eur J Med Chem; 2014 Oct; 86():613-27. PubMed ID: 25218910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis.
    Luckner SR; Liu N; am Ende CW; Tonge PJ; Kisker C
    J Biol Chem; 2010 May; 285(19):14330-7. PubMed ID: 20200152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel InhA reductase inhibitors: application of pharmacophore- and shape-based screening approach.
    Kumar UC; Bvs SK; Mahmood S; D S; Kumar-Sahu P; Pulakanam S; Ballell L; Alvarez-Gomez D; Malik S; Jarp S
    Future Med Chem; 2013 Mar; 5(3):249-59. PubMed ID: 23464516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides.
    He X; Alian A; Ortiz de Montellano PR
    Bioorg Med Chem; 2007 Nov; 15(21):6649-58. PubMed ID: 17723305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of new inhibitors of Mycobacterium tuberculosis InhA enzyme using virtual screening and a 3D-pharmacophore-based approach.
    Pauli I; dos Santos RN; Rostirolla DC; Martinelli LK; Ducati RG; Timmers LF; Basso LA; Santos DS; Guido RV; Andricopulo AD; Norberto de Souza O
    J Chem Inf Model; 2013 Sep; 53(9):2390-401. PubMed ID: 23889525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct inhibitors of InhA are active against Mycobacterium tuberculosis.
    Manjunatha UH; S Rao SP; Kondreddi RR; Noble CG; Camacho LR; Tan BH; Ng SH; Ng PS; Ma NL; Lakshminarayana SB; Herve M; Barnes SW; Yu W; Kuhen K; Blasco F; Beer D; Walker JR; Tonge PJ; Glynne R; Smith PW; Diagana TT
    Sci Transl Med; 2015 Jan; 7(269):269ra3. PubMed ID: 25568071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and evaluation of new GEQ derivatives as inhibitors of InhA enzyme and Mycobacterium tuberculosis growth.
    Chollet A; Mori G; Menendez C; Rodriguez F; Fabing I; Pasca MR; Madacki J; Korduláková J; Constant P; Quémard A; Bernardes-Génisson V; Lherbet C; Baltas M
    Eur J Med Chem; 2015 Aug; 101():218-35. PubMed ID: 26142487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based design of a novel class of potent inhibitors of InhA, the enoyl acyl carrier protein reductase from Mycobacterium tuberculosis: a computer modelling approach.
    Subba Rao G; Vijayakrishnan R; Kumar M
    Chem Biol Drug Des; 2008 Nov; 72(5):444-9. PubMed ID: 19012578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating the structural basis of arylamides to improve potency against M. tuberculosis strain through molecular dynamics simulations.
    Punkvang A; Saparpakorn P; Hannongbua S; Wolschann P; Beyer A; Pungpo P
    Eur J Med Chem; 2010 Dec; 45(12):5585-93. PubMed ID: 20888672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical synthesis and biological evaluation of triazole derivatives as inhibitors of InhA and antituberculosis agents.
    Menendez C; Chollet A; Rodriguez F; Inard C; Pasca MR; Lherbet C; Baltas M
    Eur J Med Chem; 2012 Jun; 52():275-83. PubMed ID: 22483635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docking studies on novel alkaloid tryptanthrin and its analogues against enoyl-acyl carrier protein reductase (InhA) of Mycobacterium tuberculosis.
    Tripathi A; Wadia N; Bindal D; Jana T
    Indian J Biochem Biophys; 2012 Dec; 49(6):435-41. PubMed ID: 23350278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis.
    Sullivan TJ; Truglio JJ; Boyne ME; Novichenok P; Zhang X; Stratton CF; Li HJ; Kaur T; Amin A; Johnson F; Slayden RA; Kisker C; Tonge PJ
    ACS Chem Biol; 2006 Feb; 1(1):43-53. PubMed ID: 17163639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystallographic studies on the binding of isonicotinyl-NAD adduct to wild-type and isoniazid resistant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis.
    Dias MV; Vasconcelos IB; Prado AM; Fadel V; Basso LA; de Azevedo WF; Santos DS
    J Struct Biol; 2007 Sep; 159(3):369-80. PubMed ID: 17588773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First triclosan-based macrocyclic inhibitors of InhA enzyme.
    Rodriguez F; Saffon N; Sammartino JC; Degiacomi G; Pasca MR; Lherbet C
    Bioorg Chem; 2020 Jan; 95():103498. PubMed ID: 31855823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent progress in the identification and development of InhA direct inhibitors of Mycobacterium tuberculosis.
    Lu XY; You QD; Chen YD
    Mini Rev Med Chem; 2010 Mar; 10(3):181-92. PubMed ID: 20408801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological activities of triazole derivatives as inhibitors of InhA and antituberculosis agents.
    Menendez C; Gau S; Lherbet C; Rodriguez F; Inard C; Pasca MR; Baltas M
    Eur J Med Chem; 2011 Nov; 46(11):5524-31. PubMed ID: 21944473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluation of imidazo[2,1-b]thiazole and benzo[d]imidazo[2,1-b]thiazole derivatives as Mycobacterium tuberculosis pantothenate synthetase inhibitors.
    Samala G; Devi PB; Saxena S; Meda N; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2016 Mar; 24(6):1298-307. PubMed ID: 26867485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.